Recent studies confirmed that CD8+ T cells are required for glioma growth, and patients with higher abundance of CD8+ T cells in the TME were more likely to benefit from immune checkpoint inhibitor treatment (Tumeh et al., 2014; Kane et al., 2020). Here, CD8A is linked to central nervous system cancer.